4/12/2013 | SP | Barclays to price 11.5% reverse convertibles linked to Cyberonics
|
2/15/2013 | SP | New Issue: Barclays prices $546,000 10% reverse convertibles linked to Cyberonics
|
2/7/2013 | SP | Barclays to price 10% reverse convertibles linked to Cyberonics
|
6/2/2010 | CVLM | Cyberonics buys $15.4 million of convertible debt, leaving $7 million
|
4/29/2010 | SP | New Issue: Barclays prices $1 million 10.15% reverse convertibles linked to Cyberonics
|
4/12/2010 | SP | Barclays to price 10% reverse convertibles linked to Cyberonics
|
4/6/2010 | SP | Barclays to price 10.15% reverse convertibles linked to Cyberonics
|
4/6/2010 | SP | Barclays to price 11.35% reverse convertibles linked to Cyberonics
|
3/31/2010 | SP | New Issue: Barclays prices $0.5 million 9.5% reverse convertibles linked to Cyberonics
|
3/9/2010 | SP | Barclays to price 9.5% reverse convertibles linked to Cyberonics
|
2/17/2010 | CV | Cyberonics buys back $16.8 million convertibles at discount in quarter
|
11/18/2009 | CV | Cyberonics buys $15.8 million in convertible debt for $14.3 million
|
8/20/2009 | BWCV | Cyberonics reduces debt to less than available cash balance
|
8/19/2009 | CV | Cyberonics buys $15.6 million in convertible debt for $13.8 million
|
6/3/2009 | CV | Cyberonics purchased $3.6 million more 3% convertibles since April 24
|
2/19/2009 | CV | Cyberonics buys back another $2.5 million 3% convertibles
|
2/18/2009 | CV | Cyberonics buys back $19.8 million 3% convertibles during last quarter
|
10/6/2008 | CV | Cyberonics buys back $12.7 million 3% convertibles
|
9/3/2008 | CV | Cyberonics buys back $27.6 million 3% convertibles
|
5/12/2008 | CV | Cyberonics' note hedge for 3% convertibles cancelled due to settlement
|
4/21/2008 | CVDDSS | Cyberonics settles lawsuit over 3% convertibles due 2012
|
6/14/2007 | CVDDSS | Cyberonics 10-K filing failure does not violate 3% convertible indenture
|
1/29/2007 | SS | Cyberonics makes changes to board in response to proxy contest
|
1/22/2007 | SS | Icahn-led investors support Metropolitan Capital's picks for Cyberonics board
|
10/6/2006 | BTCVDD | Cyberonics gets acceleration notice on $125 million 3% senior subordinated convertibles
|
9/12/2006 | BT | Cyberonics gets second Nasdaq delisting warning
|
9/11/2006 | BT | Cyberonics: more patients can benefit from VNS therapy for depression
|
8/4/2006 | BTCVDD | Cyberonics gets notice of default on convertibles due 2012 for delayed 10-K filing
|
8/1/2006 | BT | Cyberonics faces Nasdaq delisting
|
7/27/2006 | BT | Cyberonics enters consent agreement with banks to preclude default over late filing of 10-K
|
7/21/2006 | BTCV | Cyberonics to pay extra interest to 3% convertibles holders
|
7/18/2006 | BT | Cyberonics receives FDA real-time review approval for Perennia Lead
|
7/12/2006 | BT | Cyberonics expects delay in filing annual report as SEC conducts option grants inquiry
|
7/12/2006 | BT | Cyberonics receives FDA approval for VNS Therapy System labeling format, software
|
6/27/2006 | BT | Cyberonics says more payers may cover VNS Therapy for treatment-resistant depression
|
6/27/2006 | BT | Cyberonics receives subpoena from U.S. Attorney over stock option grants
|
5/25/2006 | BT | Two studies demonstrate long-term effects of Cyberonics VNS Therapy
|
5/25/2006 | BT | Cyberonics: suicidality, hospitalizations due to depression decline with VNS Therapy
|
5/24/2006 | BT | Cyberonics to study clinical, economic outcomes of VNS therapy in treatment-resistant depression
|
5/22/2006 | BT | Cyberonics study finds patients who respond to VNS treatment maintain improvement
|
5/17/2006 | BT | Cyberonics enrolls patients in treatment-resistant depression study
|
4/28/2006 | BT | Cyberonics launches patient registry for treatment-resistant depression, VNS therapy
|
1/19/2006 | BKBT | Cyberonics gets $40 million revolver
|
1/18/2006 | BT | Cyberonics completes VNS Therapy depression studies
|
10/21/2005 | BT | Market Commentary: Electro-Optical delays IPO again; Jerini IPO scheduled for Oct. 24 week; Affymetrix off; Cephalon higher
|
9/23/2005 | BT | Market Commentary: Nektar upsizes home-run convertible, Renovis raves, Acusphere sinks after follow-ons; Cyberonics slips
|
9/22/2005 | BT | Market Commentary: Nektar convertible at bat along with follow-ons from GTx, Renovis; Cyberonics prices wide, closes off
|
9/22/2005 | CV | Market Commentary: Citi/Genworth SYNdecs close flat; Wesco, Toreador gain, but Cyberonics drops; Nektar eyed
|
9/22/2005 | BTCV | New Issue: Cyberonics $125 million seven-year convertibles yield 3%, up 25%
|
9/21/2005 | CV | Market Commentary: Chesapeake, Devon/Chevron trade; Chiron down; Nektar launches deal; Citi/Genworth prices
|
9/20/2005 | BT | Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
|
9/20/2005 | CV | Market Commentary: US Airways, Toreador launch new deals, bringing calendar to five; Sepracor, Cephalon up
|
9/19/2005 | CV | Market Commentary: CapitalSource jumps; GM, Ford, retail names weaken; two new deals launched
|
9/19/2005 | BTCV | Cyberonics to price $125 million seven-year convertibles talked at 2.5%-3%, up 27.5%-32.5%
|
9/19/2005 | BT | Market Commentary: Viacell plunges on suspending study; StemCells rises on new filing; Inex drops on note demand
|